FTSE MIB
34.657,35 +318,03 (+0,93%) Dow Jones
39.479,16 +91,40 (+0,23%) Nasdaq
16.315,48 -30,78 (-0,19%) Nikkei 225
38.229,11 +155,13 (+0,41%) Petrolio
78,31 -0,95 (-1,20%) Bitcoin EUR
56.115,80 -1.466,66 (-2,55%)
Replimune Group, Inc. (REPL)
| Chiusura precedente | 6,73 |
| Aperto | 6,76 |
| Denaro | 6,33 x 100 |
| Lettera | 6,45 x 100 |
| Min-Max giorno | 6,38 - 6,95 |
| Intervallo di 52 settimane | 5,86 - 24,81 |
| Volume | |
| Media Volume | 1.084.479 |
| Capitalizzazione | 391,654M |
| Beta (5 anni mensile) | 1,25 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,16 |
| Prossima data utili | 16 mag 2024 - 20 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 13,56 |
- GlobeNewswire
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the grant of inducement equity awards to Emily Hill, the Company’s newly appointed Chief Financial Officer. The inducement awards consist of a non-qualified stock option to purchase 125,000 shares of the Company's common stock and restricted stock units representing 83,330 share
- GlobeNewswire
Replimune Announces Appointment of Emily Hill as Chief Financial Officer
WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial Officer. Ms. Hill was most recently CFO of the commercial stage biotech company PTC Therapeutics and has more than 15 years of experience in the biotechnology and life sciences industry having held senior financial management and
- GlobeNewswire
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
Topline data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma expected in early Q4 2023 and Biologics License Application submission anticipated in Q1/2 2024 Cost sharing collaboration in cutaneous squamous cell carcinoma in the neoadjuvant setting entered into with Incyte Data snapshot for all 141 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma expected Q4 2023 RP2 and RP3 P
